
Top biologic drugs by share of total drug costs in Canadian public plans 2020/2021
This statistic depicts the top biologic drugs by share of total drug costs within select Canadian public drug plans in 2020/2021. Top listed biologic drug was Remicade (including infliximab biosimilars) with a 3.7 percent share of total drug costs that year.